GI biotech Rhythm Pharmaceuticals files for a $86 million IPO

Comment

Shutterstock photo

Rhythm Pharmaceuticals, a clinical-stage biotech developing injectable therapies for gastrointestinal diseases, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering.

The Boston, MA-based company, which was founded in 2008, plans to list on the NASDAQ under the symbol RYTM. Rhythm Pharmaceuticals initially filed confidentially on July 15, 2014. Citi and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.

The article GI biotech Rhythm Pharmaceuticals files for a $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com